THERAPIES IN IMMUNOLOGY & INFLAMMATION
Must Know Insights From The World’s Foremost Thought Leaders
FirstView Unique Assets and Capabilities
Powered by LiMA
Leaders in Medicine Atlas, the world's largest physician directory, allows us to recruit targeted physicians for our research based on hundreds of datapoints – including where they practice and how they engage with digital content.
Robust Methodology
Thorough screening and AI-powered authentication technology ensure physician credentials and qualifications prior to survey participation.
Analytics and Charting
Survey instruments—developed by industry experts, data scientists, and analytics specialists—deliver clear analysis and actionable insights.
Extensive Coverage
Our survey reports are available for any indication where competition exists among therapeutic treatment options. These reports provide valuable insight into markets of importance to you.
What Our Clients Are Saying
“Excellent”
Director, Medical Affairs, AstraZeneca
“...this report has been very valuable”
Director, Biotech New Product Planning and Drug Delivery, Eli Lilly
Contact Us
© 2022 FirstWord. All rights reserved | 1140 Avenue of the Americas, 14th Floor, New York, NY 10036
Our Research
We engage the world’s leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
Our in-house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
View A Full List Of Therapy Trends Reports
Future Driven
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL Bulletins on the impact of market-changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunities will emerge.
Continuous Monitoring
Boardroom Ready
Short on time? All reports are supported by a convenient slide pack summarizing the core of the analysis, making it easy to share with key stakeholders.
Deep Dive
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an objective and comprehensive view of key market-shaping issues.
Leading KOLS
KOL Answers
Future Focused
What Makes KOL Insight Reports Different
Key Questions Answered
Due to its negative impact on COVID-19 vaccinations prescribing of rituximab plummeted: what are its prospects post-pandemic?
Cost concerns are impacting the use of BMS’s Orencia – are KOLs convinced its evaluation in pre-RA and prevention settings could lead to change?
Will a comprehensive clinical data package and competitive pricing be enough for Incyte/Lilly’s Olumiant to maintain its leading position in Europe?
What positive factors do experts cite that underpins the increasing use of AbbVie’s JAK inhibitor Rinvoq?
Considering safety concerns with Xeljanz and competitive alternatives, do experts see a role for generic tofacitinib?
What safety advantages do European KOLs identify that could differentiate Galapagos’ Jyseleca from competitive JAK inhibitors?
1
2
3
4
5
6
Key Therapies Covered
Anti-TNFs
dazodalibep
Interleukin-6 inhibitors
Jyseleca (filgotinib)
Olumiant (baricitinib)
Orencia (abatacept)
otilimab
Rinvoq (upadacitinib)
Rituxan/MabThera (rituximab)
Xeljanz (tofacitinib)
Partial List of Participating KOLs
Professor of Rheumatology at Montpellier University Montpellier, France
Director and Consultant in Rheumatology and Musculoskeletal Sonography at the Institut Poal de Reumatología
Barcelona, Spain
Professor of Rheumatology at Leiden University Medical Centre
Leiden, the Netherlands
Medical Director and Clinical Professor of Medicine and Rheumatology
New York City, NY, USA
Professor of Medicine at the Cleveland Clinic
Cleveland, OH, USA
Clinical Professor of Medicine at the University of Texas Southwestern Medical Center at Dallas, and co-Medical Director of the Metroplex Clinical Research Center
Dallas, TX, USA
KOL Insight: Rheumatoid Arthritis
This KOL Insight report reveals the findings from research with 12 world-renowned KOLs into the future treatment of rheumatoid arthritis. The research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.
Learn more about this report or how we can support you with additional insights. If you are already a client, log in to read the report.